Aurobindo Pharma shares gain on US FTC nod for Lannett deal; Here’s what it needs to do
Shares of Aurobindo Pharma Ltd. gained as much as 2% on Friday, June 19, after the company announced plans to divest four generic pharmaceutical products as part of the regulatory process to complete its proposed $250 million acquisition of US-based Lannett Company. The company said the products will be divested to Quagen Pharmaceuticals to address…
